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1. INTRODUCTION {#crj13144-sec-0005}
===============

Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) are the two most common causes of death worldwide, killing 3 and 1.7 million people respectively each year. COPD is a common chronic airway disease in the respiratory system characterized by continuous airflow limitation. Its morbidity and mortality are increasing year by year, and it is expected to become the third leading cause of disease death in the world by 2020. LC is the most frequently diagnosed cancer worldwide and the leading cause of cancer‐related deaths, with a 5‐year survival rate of about 10% to 20%. It has become the fifth leading cause of death worldwide.

Chronic obstructive pulmonary disease and LC are related lung diseases. Studies have shown that they share the same risk factors, such as smoking and other inhaled substances, for occupational, household or outdoor air pollution. COPD is an important risk factor for the development of LC, and LC is also an important cause of death in COPD patients. In the diagnosis of LC, non‐small cell LC (NSCLC) patients account for 80%.[1](#crj13144-bib-0001){ref-type="ref"} COPD is considered to be one of the important comorbid diseases in NSCLC patients, with a prevalence of 50%‐70%.[2](#crj13144-bib-0002){ref-type="ref"}, [3](#crj13144-bib-0003){ref-type="ref"} In the past 30 years, although the association between COPD and LC risk has been well recognized, relatively little is known about the prognostic impact of COPD in patients with LC. Several studies have investigated the effect of COPD on survival of NSCLC, but the results are not clear.

This study aims to clarify the prognosis of patients with COPD combined with NSCLC, including mortality and survival rate, through a meta‐analysis.

2. Materials and methods {#crj13144-sec-0006}
========================

2.1. Search strategy {#crj13144-sec-0007}
--------------------

The primary sources for the literature search were the following electronic databases: PubMed, Web of Science and the Medline, Published between 1950 and 2019. And no language limitation was imposed during the retrieval. The search was limited by using the following search terms: (COPD or chronic obstructive pulmonary disease) AND (non‐small cell LC or NSCLC) AND (prognosis or prognostic or outcome or survival). The title and abstract of each identified study were scanned to exclude any irrelevant publications. The remaining articles were reviewed to determine whether they contained information on the topic of interest. We also supplemented this search by examining the reference lists of all of the retrieved publications and by identifying additional relevant articles.

2.2. Eligibility criteria {#crj13144-sec-0008}
-------------------------

We formulated the following inclusion and exclusion criteria to determine the eligible studies included in our meta‐analysis.

Inclusion criteria: studies compared patients with NSCLC with and without COPD;LC was the study\'s primary disease;the target outcomes were prognosis of COPD with NSCLC, including survival and mortality;the hazard ratio (HR) with corresponding 95% confidence interval (CI) was validly reported in original literature or generated by sufficient data;

Exclusion criteria: studies had no control patients;studies cannot be found the full text;poor literature quality;letters, comments, review articles, conference proceedings, case‐reports and unpublished data.

We included more recent articles with the largest sample sizes to avoid overlapping patient data in duplicate publications, when there were duplicate publications.

2.3. Data extraction {#crj13144-sec-0009}
--------------------

Screening of potentially eligible studies was conducted independently by two authors, and disagreement being resolved by consensus. Baseline characteristics and outcomes were extracted: first author, publication year, study design, sample sizes included the number of total COPD with NSCLC and COPD, prognosis of patients in both groups.

2.4. Assessment of study quality {#crj13144-sec-0010}
--------------------------------

As for case‐control studies, we applied the Newcastle‐Ottawa Quality Assessment Scale, with a total score of 0‐3, 4‐6 and 7‐9 considered low, moderate and high quality, respectively. The quality of all studies was evaluated by a consensus meeting with all authors. Low‐quality studies were excluded from our meta‐analysis.

2.5. Statistical analysis {#crj13144-sec-0011}
-------------------------

Review Manager 5.3 software was used to conduct statistical analysis on the strength of the association between NSCLC and COPD, and calculate the odd ratio (OR) of effect indicators and 95% confidence interval (95% CI) of each study. Heterogeneity test should be performed before merging effect size. When the heterogeneity test result is *P* \> 0.10 and *I* ^2^ ≤ 50%, it can be considered that there is homogeneity among multiple similar studies. Fixed effect model is used to calculate the combined effect quantity, and the random effect model is used to calculate the combined effect size. The forest plot and funnel plot of meta‐analysis results were drawn.

3. Results {#crj13144-sec-0012}
==========

3.1. Literature search {#crj13144-sec-0013}
----------------------

Figure [1](#crj13144-fig-0001){ref-type="fig"} presents the flowchart for identification of relevant studies. In total, we identified 851 records in the electronic databases. After initial screening based on titles and abstracts with predefined inclusion/exclusion criteria, 150 articles were identified for full‐text review. Eventually, 11 case‐control studies were included in this systematic review and meta‐analysis. Detailed characteristics of included studies are provided in Table [1](#crj13144-tbl-0001){ref-type="table"}.

![A flow chart showing the procedure for identifying the studies included in the meta‐analysis](CRJ-14-389-g001){#crj13144-fig-0001}

###### 

Characters of included studies

  Study source                                                                                                                                          Study design            Study population   Gender (m/f)   Age, years, mean   Follow‐up, months   COPD ascertainment          Outcomes   HR estimation          Multivariate analysis                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------ -------------- ------------------ ------------------- --------------------------- ---------- ---------------------- ---------------------------- ------------------ -----
  1 <http://nc.yuntsg.com/pubmed/?term=Omote%2520N%255BAuthor%255D%26cauthor=true%26cauthor_uxml:id=29270008> [4](#crj13144-bib-0004){ref-type="ref"}   CS                      85                 43             42                 COPD: 37/6          COPD: 67 ± 8                NR         GOLD                   OR                           Reported in text   Yes
  Non‐COPD: 32/10                                                                                                                                       Non‐COPD: 63 ± 8                                                                                                                                                                                               
  2 Media Ara Shwan[5](#crj13144-bib-0005){ref-type="ref"}                                                                                              CS                      534                329            141                COPD: 191/138       COPD: 69.4 ± 9.0            60         Medical record         5‐year survival              Reported in text   Yes
  Non‐COPD: 68/73                                                                                                                                       Non‐COPD: 65.9 ± 10.4   Spirometry                                                                                                                                                                             
  3 Takaki Akamine[6](#crj13144-bib-0006){ref-type="ref"}                                                                                               CS                      548                167            381                COPD: 129/38        Never smokers: 67.7 ± 9.9   38         Spirometry             RFS                          Reported in text   Yes
  Non‐COPD: 185/196                                                                                                                                     Smokers: 67.9 ± 9.4     CSS                                                                                                                                                                                    
  OS                                                                                                                                                                                                                                                                                                                                                                   
  4 Nader Mina[7](#crj13144-bib-0007){ref-type="ref"}                                                                                                   CS                      107                88             19                 NR                  NR                          12         Spirometry and/or CT   One/Two year survival rate   Reported in text   Yes
  24                                                                                                                                                                                                                                                                                                                                                                   
  5 Seung Jun Lee[8](#crj13144-bib-0008){ref-type="ref"}                                                                                                CS                      221                111            110                COPD: 97.3%/2.7%    COPD: 67.3 ± 8.0            24         GOLD                   OS                           Reported in text   Yes
  Non‐COPD: 96.4%/3.6%                                                                                                                                  Non‐COPD: 62.1 ± 10.3   60                                                                                                                                                                                     
  6 Ju S[9](#crj13144-bib-0009){ref-type="ref"}                                                                                                         CS                      110                57             53                 COPD: 52/5          COPD: 67.5 ± 7.4            21         ATS                    OS                           Reported in text   Yes
  Non‐COPD: 44/9                                                                                                                                        Non‐COPD: 65.2 ± 7.8    ERS                PFS                                                                                                                                                                 
  7 Maria Iachina[10](#crj13144-bib-0010){ref-type="ref"}                                                                                               CS                      10 378             845            7278               COPD: 452/393       NR                          NR         Medical record         survival                     Reported in text   Yes
  Non‐COPD: 3568/3710                                                                                                                                                                                                                                                                                                                                                  
  8 Yi Young‐Soo[11](#crj13144-bib-0011){ref-type="ref"}                                                                                                CS                      337                170            167                COPD: 154/16        COPD: 70.4 ± 8.9            25         GOLD                   Quality of life survival     Reported in text   Yes
  Non‐COPD: 108/59                                                                                                                                      Non‐COPD: 63.2 ± 11.6                                                                                                                                                                                          
  9 Rihong Zhai[12](#crj13144-bib-0012){ref-type="ref"}                                                                                                 CS                      902                330            572                NR                  COPD: 66.8 ± 9.7            60         Doctor‐diagnosis       OS                           Reported in text   Yes
  Non‐COPD: 67.1 ± 10.1                                                                                                                                 PFS                                                                                                                                                                                                            
  10 Lim Jeong Uk[13](#crj13144-bib-0013){ref-type="ref"}                                                                                               CS                      345                68             277                COPD: 30/38         Median age: COPD75.2        NR         ATS                    OS                           Reported in text   Yes
  Non‐COPD: 54/223                                                                                                                                      Non‐COPD64.2            ERS                                                                                                                                                                                    
  11 J.A. Gullón[14](#crj13144-bib-0014){ref-type="ref"}                                                                                                CS                      353                164            189                NR                  NR                          24         Spirometry             Survival                     Reported in text   Yes
  12 Yasuo Sekine[15](#crj13144-bib-0015){ref-type="ref"}                                                                                               CS                      244                78             166                COPD: 58/20         COPD: 65.3 ± 7.9            24‐60      Spirometry             OS                           Reported in text   No
  Non‐COPD: 95/71                                                                                                                                       Non‐COPD: 63.6 ± 9.7                                                                                                                                                                                           

John Wiley & Sons, Ltd

The sample sizes for different studies of NSCLC ranged from 85 to 10 378, with a total number of 14 164, including COPD 2450 and Non‐COPD 9395. 12 case‐control studies were conducted in Korea,[8](#crj13144-bib-0008){ref-type="ref"}, [9](#crj13144-bib-0009){ref-type="ref"}, [11](#crj13144-bib-0011){ref-type="ref"}, [13](#crj13144-bib-0013){ref-type="ref"} Denmark,[5](#crj13144-bib-0005){ref-type="ref"}, [9](#crj13144-bib-0009){ref-type="ref"} Japan,[4](#crj13144-bib-0004){ref-type="ref"}, [6](#crj13144-bib-0006){ref-type="ref"}, [15](#crj13144-bib-0015){ref-type="ref"} the United States[7](#crj13144-bib-0007){ref-type="ref"}, [12](#crj13144-bib-0012){ref-type="ref"} and Spain.[14](#crj13144-bib-0014){ref-type="ref"} In terms of diagnosis of COPD, 4 studies used Spirometry,[5](#crj13144-bib-0005){ref-type="ref"}, [6](#crj13144-bib-0006){ref-type="ref"}, [14](#crj13144-bib-0014){ref-type="ref"}, [15](#crj13144-bib-0015){ref-type="ref"} 3 studies used GOLD guideline,[4](#crj13144-bib-0004){ref-type="ref"}, [8](#crj13144-bib-0008){ref-type="ref"}, [11](#crj13144-bib-0011){ref-type="ref"} 2 studies used American Thoracic Society criteria or European Respiratory Society criteria,[9](#crj13144-bib-0009){ref-type="ref"}, [13](#crj13144-bib-0013){ref-type="ref"} 1 studies used Spirometry and/or Computed tomography (CT),[7](#crj13144-bib-0007){ref-type="ref"} 1 studies used Medical record[10](#crj13144-bib-0010){ref-type="ref"} and 1 studies used doctor‐diagnosis.[12](#crj13144-bib-0012){ref-type="ref"}

As for quality assessment, the case‐control studies had a moderate to high quality (Newcastle‐Ottawa Quality Assessment Scale score 4‐9). Details of specific assessment are listed in Table [2](#crj13144-tbl-0002){ref-type="table"}.

###### 

Assessment quality of included studies

  Source                                                                                                                                                Choose                     Comparability   Measurement of exposure factors   Score                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------- --------------------------------- -------------- ------------------------------------------- ----------------- ----- --------------- ---
  1 <http://nc.yuntsg.com/pubmed/?term=Omote%2520N%255BAuthor%255D%26cauthor=true%26cauthor_uxml:id=29270008> [4](#crj13144-bib-0004){ref-type="ref"}   Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  2 Media Ara Shwan[5](#crj13144-bib-0005){ref-type="ref"}                                                                                              Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  3 Takaki Akamine[6](#crj13144-bib-0006){ref-type="ref"}                                                                                               Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  4 Nader Mina[7](#crj13144-bib-0007){ref-type="ref"}                                                                                                   Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  5 Seung Jun Lee[8](#crj13144-bib-0008){ref-type="ref"}                                                                                                Independent verification   Yes             Community control                 Without COPD   Did not control for age and other factors   Medical records   Yes   Not described   4
  6 Ju S[9](#crj13144-bib-0009){ref-type="ref"}                                                                                                         Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  7 Maria Iachina[10](#crj13144-bib-0010){ref-type="ref"}                                                                                               Independent verification   Yes             Community control                 Without COPD   Control for age and other factors           Medical records   Yes   Not the same    7
  8 Yi Young‐Soo[11](#crj13144-bib-0011){ref-type="ref"}                                                                                                Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  9 Rihong Zhai[12](#crj13144-bib-0012){ref-type="ref"}                                                                                                 Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
  10 Lim Jeong Uk[13](#crj13144-bib-0013){ref-type="ref"}                                                                                               Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   The same        7
  11 J.A. Gullón[14](#crj13144-bib-0014){ref-type="ref"}                                                                                                Independent verification   Yes             Community control                 Without COPD   Control for age and other factors           Medical records   Yes   Not described   7
  12 Yasuo Sekine[15](#crj13144-bib-0015){ref-type="ref"}                                                                                               Independent verification   Yes             Hospital control                  Without COPD   Control for age and other factors           Medical records   Yes   Not described   6
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3.2. The prognosis of NSCLC with COPD {#crj13144-sec-0014}
-------------------------------------

A total of 12 studies evaluated the association between NSCLC and COPD. Meta‐analyses showed that concomitant COPD was associated with poorer OS compared with patients without COPD (Fixed: HR: 1.16; 95% CI: 1.08‐1.25. Random: HR: 1.07; CI: 0.92, 1.24) with a significant heterogeneity across studies (*I* ^2^ = 45%, *P* = 0.04) (Figure [2](#crj13144-fig-0002){ref-type="fig"}).

![Forest plots of the associations between concomitant COPD and non‐small cell lung (the fixed effects model and random effects model)](CRJ-14-389-g002){#crj13144-fig-0002}

3.3. Publication bias {#crj13144-sec-0015}
---------------------

The left and right sides of the funnel plot are basically symmetric by visual inspection that indicated no significant publication bias was found in this meta‐analysis (Figure [3](#crj13144-fig-0003){ref-type="fig"}).

![Funnel plots to assess publication bias regarding the association between concomitant chronic obstructive pulmonary disease and non‐small cell LC overall survival (A is the funnel plots corresponding to the fixed effect model; B is the funnel plots corresponding to the random effect model)](CRJ-14-389-g003){#crj13144-fig-0003}

4. DISCUSSION {#crj13144-sec-0016}
=============

Our meta‐analysis based on the prognosis of NSCLC with COPD showed that NSCLC patients with COPD were associated with poor prognosis (Fixed: HR: 1.16; 95%CI: 1.08‐1.25. Random: HR: 1.07; CI: 0.92‐1.24), with a significant heterogeneity between studies (*I* ^2^ = 45%, *P* = 0.04). It suggests that the prognosis of patients with NSCLC complicated with COPD is poor, and the survival rate is reduced and the mortality rate is increased. Previous studies have found that COPD is an important factor in the occurrence and development of LC. Therefore, in the diagnosis and treatment of NSCLC, attention should be paid to the screening of coexisting COPD, so as to early detection and treatment and improve the prognosis of patients with NSCLC complicated with COPD.

The prognosis of LC is poor, and the 5‐year survival rate is about 10%‐15%. In the diagnosis of LC, NSCLC is the main one. The number of new cases is expected to increase as the population ages, and LC patients will increasingly coexist with the disease. As another common respiratory disease, COPD, the incidence and mortality are also increasing year by year, and it is also one of the important comorbid diseases of LC patients, which has been widely reported as an important factor in the occurrence and development of LC.[16](#crj13144-bib-0016){ref-type="ref"}, [17](#crj13144-bib-0017){ref-type="ref"}, [18](#crj13144-bib-0018){ref-type="ref"} At present, there are many reports on the impact of COPD on the prognosis of NSCLC, but opinions are not uniform. Maria Iachina et al. showed that the survival rate of NSCLC patients with COPD significantly decreased,[6](#crj13144-bib-0006){ref-type="ref"}, [10](#crj13144-bib-0010){ref-type="ref"}, [11](#crj13144-bib-0011){ref-type="ref"}, [12](#crj13144-bib-0012){ref-type="ref"}, [13](#crj13144-bib-0013){ref-type="ref"}, [14](#crj13144-bib-0014){ref-type="ref"}, [15](#crj13144-bib-0015){ref-type="ref"} and Norihito Omote et al showed that mild to moderate COPD had no significant adverse effect on the prognosis of NSCLC patients.[4](#crj13144-bib-0004){ref-type="ref"}, [5](#crj13144-bib-0005){ref-type="ref"}, [7](#crj13144-bib-0007){ref-type="ref"}, [8](#crj13144-bib-0008){ref-type="ref"}, [9](#crj13144-bib-0009){ref-type="ref"} Our meta‐analysis showed that NSCLC with COPD had a poor prognosis, similar to the results of Maria Iachina et al. Besides, Maria Iachina contributed significantly to the study, accounting for 67.9% (Fixed effect model), which seemed to be related to the large proportion of the total sample size included and the large proportion of the sample size of NSCLC without COPD.

The fixed effects model of meta‐analysis is based on the assumption that a number of studies have a common effect scale, and the difference in the effect scale of each study is mainly caused by random error. However, the random effects model assumes that each study does not have a common effect scale, but each study has its own effect scale, and a balance is obtained by using the inter‐group and intra‐group differences. In our study, we included studies from different parts of the world with very different survival environments and demographic characteristics, as well as different rates of COPD and NSCLC. In this study, the fixed effects model and the random effects model have the same *P* value and *I* ^2^ value. However, it is not appropriate to use the same effect scale in the fixed effects model to measure these studies, for example, the contribution of J.A. Gullon's research is ignored in the solid effects model that we adopted. Therefore, the random effects model seems to be more appropriate, which allows the heterogeneity of each included sample, and the weight of each sample is more suitable for this study than the fixed effect model. However, several limitations should be taken into account when interpreting our study. First, there are relatively few participants. The total is still not large enough to reduce statistical significance; Second, we failed to include high‐quality randomized controlled trials; Third, no further analysis was conducted on the effects of different grades of COPD on the prognosis of NSCLC and on the prognosis of different stages of NSCLC. Fourth, this study did not search the Chinese literature, which may exclude several studies aimed at exploring the relationship between COPD and NSCLC in Chinese.
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